FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * DOCHERTY JOHN MARTIN 2. Issuer Name and Ticker or Trading Symbol Lexaria Bioscience Corp. [ LEXX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President
(Last)         (First)         (Middle)
23 MIKELEN DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
6/8/2021
(Street)
PORT PERRY, A6 L9L 1V1
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
common shares                 54075  I  Private Holding Company 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options  $9.6                  4/23/2020  4/23/2025  Common Shares  13334    13334  D   
Stock Options  $5.31                  4/26/2021  4/26/2026  Common Shares  18000    31334  D   
Stock Options  $7.08  6/8/2021    A     18334      6/8/2021  6/8/2026  Common Shares  18334  $0  49668  D   

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DOCHERTY JOHN MARTIN
23 MIKELEN DRIVE
PORT PERRY, A6 L9L 1V1
X
President

Signatures
/John Docherty/ 6/9/2021
**Signature of Reporting Person Date
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Lexaria Bioscience Charts.
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Lexaria Bioscience Charts.